Search results
Results from the WOW.Com Content Network
The PHQ-9 (DEP-9 in some sources [13]), a tool specific to depression, scores each of the 9 DSM-IV related criteria based on the mood module from the original PRIME-MD. [14] The PHQ-9 is both sensitive and specific in its diagnoses, which has led to its prominence in the primary care setting.
Timolol, propranolol; Propranolol is the only agent indicated for the control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in phaeochromocytoma. [45]
Propranolol may cause harmful effects for the baby if taken during pregnancy; [7] however, its use during breastfeeding is generally considered to be safe. [8] It is a non-selective beta blocker which works by blocking β-adrenergic receptors. [2] Propranolol was patented in 1962 and approved for medical use in 1964. [9]
The K-SADS-PL is used to screen for affective and psychotic disorders as well as other disorders, including, but not limited to Major Depressive Disorder, Mania, Bipolar Disorders, Schizophrenia, Schizoaffective Disorder, Generalized Anxiety, Obsessive Compulsive Disorder, Attention Deficit Hyperactivity Disorder, Conduct Disorder, Anorexia Nervosa, Bulimia, and Post-Traumatic Stress Disorder. [4]
The Veterans Administration, Department of Defense, and Kaiser Permanente adopted the PHQ-9 as a standard measure for depression screening. The PHQ-9 is also the most commonly used depression measure in the United Kingdom's National Health Service, which requires providers to use a depression screening instrument when treating depression. [13]
The main indication for SSRIs is major depressive disorder; however, they are frequently prescribed for anxiety disorders, such as social anxiety disorder, generalized anxiety disorder, panic disorder, obsessive–compulsive disorder (OCD), eating disorders, chronic pain, and, in some cases, for posttraumatic stress disorder (PTSD).
[15] [16] Propranolol and topiramate have the best evidence in children; however, evidence only supports short-term benefit as of 2020. [8] [17] The beta blocker timolol is also effective for migraine prevention and in reducing migraine attack frequency and severity. [15]
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia.It was published in 1987 by Stanley Kay, Lewis Opler, and Abraham Fiszbein.